Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Sonnet BioTherapeutics Holdings, Inc. from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Sonnet BioTherapeutics Holdings, Inc. annual and quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • Sonnet BioTherapeutics Holdings, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Dec 2024 was $4,712,047, a 531% increase year-over-year.
  • Sonnet BioTherapeutics Holdings, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2025 was $13,207,810.
  • Sonnet BioTherapeutics Holdings, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $2,124,803, a 173% decline from 2023.
  • Sonnet BioTherapeutics Holdings, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $778,620, a 97% increase from 2022.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)

Sonnet BioTherapeutics Holdings, Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $13,207,810 +$15,332,613 01 Oct 2024 30 Sep 2025 10-K 16 Dec 2025 2025 FY
2024 $2,124,803 -$1,346,183 -173% 01 Oct 2023 30 Sep 2024 10-K 16 Dec 2025 2025 FY
2023 $778,620 +$23,790,568 +97% 01 Oct 2022 30 Sep 2023 10-K 17 Dec 2024 2024 FY
2022 $24,569,188 -$44,841,352 -221% 01 Oct 2021 30 Sep 2022 10-K 14 Dec 2023 2023 FY
2021 $20,272,164 +$12,957,914 +177% 01 Oct 2020 30 Sep 2021 10-K 15 Dec 2022 2022 FY
2020 $7,314,250 +$7,337,344 01 Oct 2019 30 Sep 2020 10-K 17 Dec 2021 2021 FY
2019 $23,094 +$1,019,038 +98% 01 Jan 2019 31 Dec 2019 10-K 19 Mar 2020 2019 FY
2018 $1,042,132 -$1,212,050 -713% 01 Jan 2018 31 Dec 2018 10-K 19 Mar 2020 2019 FY
2017 $169,918 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY

Sonnet BioTherapeutics Holdings, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $4,712,047 +$3,964,914 +531% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025 2024 Q1
Q4 2023 $747,133 +$2,099,408 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025 2024 Q1
Q4 2022 $1,352,275 +$6,860,074 +84% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024 2024 Q1
Q4 2021 $8,212,349 -$3,210,542 -64% 01 Oct 2021 31 Dec 2021 10-Q 13 Feb 2023 2023 Q1
Q4 2020 $5,001,807 -$5,855,647 -686% 01 Oct 2020 31 Dec 2020 10-Q 08 Feb 2022 2022 Q1
Q1 2020 $48,249 +$116,366 01 Jan 2020 31 Mar 2020 10-Q 18 May 2020 2020 Q1
Q4 2019 $853,840 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021 2021 Q1
Q1 2019 $68,117 -$143,289 -191% 01 Jan 2019 31 Mar 2019 10-Q 18 May 2020 2020 Q1
Q1 2018 $75,172 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.